Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia

JAMA Oncol. 2016 Jun 1;2(6):828-9. doi: 10.1001/jamaoncol.2016.1005.

Authors

Seongseok Yun¹, Nicole D Vincelette², Ivo Abraham³

Affiliations

¹ Department of Medicine, University of Arizona, Tucson.
² Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
³ Arizona Cancer Center, University of Arizona, Tucson4Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson.

PMID: 27281623
DOI: 10.1001/jamaoncol.2016.1005

No abstract available

MeSH terms

Cardiotoxicity / physiopathology
Cardiovascular Abnormalities / chemically induced
Cardiovascular Abnormalities / physiopathology*
Humans
Imatinib Mesylate / adverse effects*
Imatinib Mesylate / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors
Imatinib Mesylate